PSC
CRNX icon

Piper Sandler & Co’s Crinetics Pharmaceuticals CRNX Stock Holding History

Piper Sandler & Co’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-162
Closed -$4K – 20
2019
Q1 		$4K Buy
+162
New +$3.98K ﹤0.01% 12

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Piper Sandler & Co's CRNX Position: Q2 2019 in Review

Piper Sandler & Co sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2019, closing a stake of 162 shares — an estimated $4K sold.

Piper Sandler & Co first reported a position in CRNX in Q1 2019 and held it in 1 quarter. The position peaked at $4K in Q1 2019. 63 funds tracked by Wall St. Rank hold CRNX as of Q2 2019.

  • Piper Sandler & Co reported no remaining Crinetics Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Piper Sandler & Co sold 162 Crinetics Pharmaceuticals shares in Q2 2019, an estimated $4K.
  • Piper Sandler & Co first reported a position in Crinetics Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Piper Sandler & Co's Crinetics Pharmaceuticals position peaked at $4K in Q1 2019.
  • 63 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2019.

Based on Piper Sandler & Co's 13F filing for Q2 2019, filed 14 Aug 2019.